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Synthesis of 5-nitrosalicylanilide derivatives with potential antibacterial activity
Diploma thesis
Charles University in Prague, Faculty of Pharmacy in Hradec Kralove
Pharmacy
Background: The aim of this diploma thesis was the synthesis of 5-
nitrosalicylanilide derivatives as a potential anti-tuberculosis agent.
Methods: The reactions were monitored, and the purity of products was 
verified by thin layer chromatography in which the plates were coated with 
silica gel 60 F254 and seen by using UV irradiation. Column chromatography 
was done using silica gel 60.
The melting points of produced compounds were shown on a Melting 
Point apparatus, IR spectra were recorded using the technique of ART and 
the NMR spectra were measured in CDCl3 or DMSO-d6
Results: The starting compounds were generally reacted with success under 
the presence of chlorobenzene, trimethylamine and phosphorus trichloride 
and the microwave reactor.
Conclusion: Unfortunately the final products of these experiments had 
impurities of phenolate salts.
Abstrakt 
Kourtidou Maria 
Syntéza 5-nitrosalicylanilidových derivátů s potenciální antibakteriální aktivitou 
Diplomová práce 
Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové 
Cíl: Cílem této diplomové práce byla syntéza několika 5-nitrosalicylanilidových 
derivátů s potenciální antituberkulózní aktivitou. 
Metody: Průběh reakcí a čistota produktů byly monitorovány chromatografií 
na tenké vrstvě na deskách potažených silikagelem 60 F254 za použití detekce 
UV záření. Chromatografie na koloně byla provedena na silikagelu 60. 
Teploty tání připravených sloučenin byly měřeny na bodotávku Büchi a 
jsou uvedeny bez korekce, IČ spektra byla měřena technikou ART a NMR 
spektra byla měřena v CDCI3 nebo DMSO-d6. 
Výsledky: Kondenzační reakce byly prováděny v mikrovlnném reaktoru. 
Výchozí sloučeniny se ponechaly reagovat v chlorbenzenu za přítomnosti 
triethylaminu a chloridu fosforitého. 
Závěr: Podle interpretace NMR spekter jsou některé konečné produkty patrně 
ve formě triethylamoniových solí. 
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1. General aspects of Tuberculosis
1.1 Introduction
Speaking about the disease of Tuberculosis (TB), it could be said that 
this is actually a disease caused by the bacteria called Mycobacterium 
tuberculosis1. Specific bacteria usually attack the lungs, but they can also 
damage other parts of the body. It should also be mentioned that the TB 
spreads through the air when a person with TB of the lungs or throat coughs, 
sneezes, or talks. If patients have been exposed, they should go to their
doctor for tests. Patients have to be more likely to get TB if they have a weak 
immune system2.
About the symptoms of TB in the lungs, those may include the
following:
ÿ A bad cough that lasts 3 weeks or longer
ÿ Weight loss
ÿ Loss of appetite
ÿ Coughing up blood or mucus
ÿ Weakness or fatigue
ÿ Fever
ÿ Night sweats
But it could also be said that except from the above, there are also skin 
tests, blood tests, x-rays, and other tests can tell if people have TB. If not 
treated properly, TB can be deadly for them. They can also usually cure active 
TB by taking several medicines for a long period of time1.
1.2 Signs and Symptoms of TB Disease
As to the signs and symptoms of the TB disease, people could not 
notice any symptoms of illness until the disease is quite advanced. Even then 
the symptoms loss of weight, loss of energy, poor appetite, fever, a productive 
cough, and night sweats -- might easily be blamed on another disease3. It is 
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noticeable that only about 10% of people infected with M. tuberculosis ever 
develop tuberculosis disease. Many of those who suffer TB do so in the first 
few years following infection, but the bacillus may lie dormant in the body for 
decades2.
Although most initial infections have no symptoms and people 
overcome them, they may develop fever, dry cough, and abnormalities that 
may be seen on a chest X-ray. This is called primary pulmonary tuberculosis.
Pulmonary tuberculosis frequently goes away by itself, but in 50%-60% of 
cases, the disease can return4. Tuberculous pleuritis may occur in 10% of 
people who have the lung disease from tuberculosis. The pleural disease 
occurs from the rupture of a diseased area into the pleural space, the space 
between the lung and the lining of the abdominal cavity3.
Those people have a nonproductive cough, chest pain, and fever. The 
disease may go away and then come back at a later date. In a minority of 
people with weakened immune systems, TB bacteria may spread through 
their blood to various parts of the body. This is called military tuberculosis and 
produces fever, weakness, loss of appetite, and weight loss. Cough and 
difficulty breathing are less common1.
Generally, return of dormant tuberculosis infection occurs in the upper 
lungs. Symptoms include common cough with a progressive increase in 
production of mucus and coughing up blood. Other symptoms could include 
the following2:
v fever
v loss of appetite
v weight loss, and
v night sweats
Except from the above, it is also mentioned that about 15% of people 
may develop tuberculosis in an organ other than their lungs. In advance, 
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about 25% of these people usually had known TB with inadequate treatment. 
The most common sites include the following2:
ÿ lymph nodes,
ÿ genitourinary tract,
ÿ bone and joint sites,
ÿ meninges, and
ÿ lining covering the outside of the gastrointestinal tract
1.3 The Bacteria of TB
Speaking about the bacteria of the Tuberculosis (TB), it is mentioned 
actually that TB is an infectious disease that is caused by a bacterium called 
Mycobacterium tuberculosis4. TB primarily affects the lungs, but it can also 
affect organs in the central nervous system, lymphatic system, and circulatory 
system among others. The disease was called "consumption" in the past 
because of the way it would consume from within anyone who became 
infected5.
According to Medilexicon`s medical dictionary, tuberculosis is "A 
specific disease caused by infection with Mycobacterium tuberculosis, the 
tubercle bacillus, which can affect almost any tissue or organ of the body, the 
most common site of the disease being the lungs"4.
When a person becomes infected with tuberculosis, the bacteria in the 
lungs multiply and cause pneumonia along with chest pain, coughing up 
blood, and a prolonged cough. In addition, lymph nodes near the heart and 
lungs become enlarged4. As the TB tries to spread to other parts of the body, 
it is often interrupted by the body's immune system3. 
The immune system forms scar tissue or fibrosis around the TB 
bacteria and this helps fight the infection and prevents the disease from 
spreading throughout the body and to other people. If the body's immune 
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system is unable to fight TB or if the bacteria break through the scar tissue, 
the disease returns to an active state with pneumonia and damage to kidneys, 
bones, and the meninges that line the spinal cord and brain4. 
TB is generally classified as being either latent or active. Latent TB 
occurs when the bacteria are present in the body, but this state is inactive and 
presents no symptoms. Latent TB is also not contagious. Active TB is 
contagious and is the condition that can make you sick with symptoms5. TB is 
a major cause of illness and death worldwide, especially in Africa and Asia. 
Each year the disease kills almost 2 million people. The disease is also 
prevalent among people with HIV/AIDS2.
Finally, it is mentioned that Tuberculosis is ultimately caused by the 
Mycobacterium tuberculosis that is spread from person to person through 
airborne particles. It is not guaranteed, though, that you will become infected 
with TB if you inhale the infected particles. Some people have strong enough 
immune systems that quickly destroy the bacteria once they enter the body. 
Others will develop latent TB infection and will carry the bacteria but will not 
be contagious and will not present symptoms. Still others will become 
immediately sick and will also be contagious3.
1.4 Diagnosis of TB Diseases
As to the way of diagnosis in TB Disease, it is actually mentioned that 
TB is a disease that is spread through the air from one person to another. 
There are two kinds of tests that are used to determine if a person has been 
infected with TB bacteria: the tuberculin skin test and TB blood tests4. A 
positive TB skin test or TB blood test only tells that a person has been 
infected with TB bacteria. It does not tell whether the person has latent TB 
infection (LTBI) or has progressed to TB disease. Other tests, such as a chest 
x-ray and a sample of sputum, are needed to see whether the person has TB 
disease3. Based on the above, the diagnosis of TB disease could be made 
upon the following ways.
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ÿ Tuberculin skin test: The TB skin test (also called the Mantoux 
tuberculin skin test) is performed by injecting a small amount of fluid 
(called tuberculin) into the skin in the lower part of the arm. A person 
given the tuberculin skin test must return within 48 to 72 hours to have 
a trained health care worker look for a reaction on the arm. The health 
care worker will look for a raised, hard area or swelling, and if present, 
measure its size using a ruler. Redness by itself is not considered part 
of the reaction. The skin test result depends on the size of the raised, 
hard area or swelling. It also depends on the person’s risk of being 
infected with TB bacteria and the progression to TB disease if infected.
ÿ Positive skin test: This means the person’s body was infected with TB 
bacteria. Additional tests are needed to determine if the person has 
latent TB infection or TB disease. A health care worker will then 
provide treatment as needed.
ÿ Negative skin test: This means the person’s body did not react to the 
test, and that latent TB infection or TB disease is not likely.
ÿ TB blood tests: TB blood tests (also called interferon-gamma release 
assays or IGRAs) measure how the immune system reacts to the 
bacteria that cause TB. An IGRA measures how strong a person’s 
immune system reacts to TB bacteria by testing the person’s blood in a 
laboratory.
It should be said that two IGRAs are approved by the U.S. Food and 
Drug Administration (FDA) and are available in the United States as follows1:
v QuantiFERON®–TB Gold In-Tube test (QFT-GIT)
v T-SPOT®.TB test (T-Spot)
ÿ Positive IGRA: This means that the person has been infected with TB 
bacteria. Additional tests are needed to determine if the person has 
latent TB infection or TB disease. A health care worker will then 
provide treatment as needed.
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ÿ Negative IGRA: This means that the person’s blood did not react to the 
test and that latent TB infection or TB disease is not likely.
IGRAs are the preferred method of TB infection testing for the 
following:
v People who have received bacille Calmette–Guérin (BCG). BCG is a 
vaccine for TB disease.
v People who have a difficult time returning for a second appointment to 
look for a reaction to the TST.
ÿ Testing for TB in BCG-Vaccinated Persons - Many people born outside 
of the United States have been BCG-vaccinated. People who have had 
a previous BCG vaccine may receive a TB skin test. In some people, 
BCG may cause a positive skin test when they are not infected with TB 
bacteria. If a TB skin test is positive, additional tests are needed.
IGRAs, unlike the TB skin tests, are not affected by prior BCG 
vaccination and are not expected to give a false-positive result in 
people who have received BCG.
Mentioned to the way of choosing a TB Test, it could be said that the 
person’s health care provider should choose which TB test to use. Factors in 
selecting which test to use include the reason for testing, test availability, and 
cost. Generally, it is not recommended to test a person with both a TST and 
an IGRA4. If a person is found to be infected with TB bacteria, other tests are 
needed to see if the person has TB disease3.
TB disease can be diagnosed by medical history, physical examination, 
chest x-ray, and other laboratory tests. TB disease is treated by taking 
several drugs as recommended by a health care provider. If a person does 
not have TB disease, but has TB bacteria in the body, then latent TB infection 
is diagnosed. The decision about treatment for latent TB infection will be 
based on a person’s chances of developing TB disease2.
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In case people suspected of having TB disease should be referred for 
a medical evaluation, which will include the following details:
ÿ Medical history
ÿ Physical examination
ÿ Test for TB infection (TB skin test or TB blood test)
ÿ Chest radiograph (X-ray)
ÿ Appropriate laboratory tests
1.5 Treatment of TB Disease
The treatment for tuberculosis depends on which type you have, 
although a long course of antibiotics is most often used. While TB is a serious 
condition that can be fatal if left untreated, deaths are rare if treatment is 
completed. For most people, hospital admission during treatment is not 
necessary1. In case of pulmonary TB, if patients are diagnosed with active 
pulmonary TB (TB that affects their lungs and causes symptoms), they will be 
referred to a specialist TB treatment team. This is a team of healthcare 
professionals with experience in treating TB. Patients’ TB treatment team may 
include3:
ÿ a respiratory physician - a doctor who specializes in conditions that 
affect the lungs and breathing
ÿ an infectious disease specialist
ÿ a TB nurse
ÿ a health visitor - a qualified nurse with extra training who helps 
families with babies and young children to stay healthy
ÿ Patients’ GP
ÿ a paediatrician (if necessary) - a doctor who specialises in conditions 
that affect children
It is also likely that patients will be assigned a key worker. This 
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is usually a nurse, health visitor or social care support worker who will be the 
point of contact between patients and the rest of the team and will help co-
ordinate the care6. Moreover, pulmonary TB is treated using a six-month 
course of a combination of antibiotics. The usual course of treatment is:
ÿ two antibiotics - isoniazid and rifampicin - every day for six months
ÿ two additional antibiotics - pyrazinamide and ethambutol - every day 
for the first two months
However, patients may only need to take these antibiotics three times a 
week if they need supervision5. It may be several weeks or months before 
they start to feel better. The exact length of time will depend on their overall 
health and the severity of their TB. After taking the medicine for two weeks, 
most people are no longer infectious and feel much better. However, it 
is important for patients to continue taking their medicine exactly as 
prescribed and to complete the whole course of antibiotics3.
Taking medication for six months is the most effective method of 
ensuring that the TB bacteria are killed. If patients stop taking antibiotics 
before they complete the course, or if they skip a dose, the TB infection may 
become resistant to the antibiotics. This is potentially serious, as it can be 
difficult to treat and will require a longer course of treatment3.
If treatment is completed correctly, you should not need any further 
checks by a TB specialist afterwards. However, they may be given advice 
about spotting signs that the illness has returned - although this is rare. In rare 
cases, TB can be fatal even with treatment. Death can occur if the lungs 
become too damaged to work properly1.
In the case of extrapulmonary TB (TB that occurs outside the lungs) 
can be treated using the same combination of antibiotics as those used to 
treat pulmonary TB. However, they may need to take them for 12 months. If 
patients have TB that affects your brain, you may also be prescribed a 
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corticosteroid, such as prednisolone, for several weeks to take at the same 
time as your antibiotics. This will help reduce any swelling in the affected 
areas (Ferguson et al, 2006). As with pulmonary TB, it is important for 
patients to take their medicines exactly as prescribed and to finish the 
course4.
In the case of the latent TB, this is where people have been infected 
with the TB bacteria but do not have any symptoms of active 
disease. Treatment for latent TB is usually recommended for2:
ÿ people 35 years of age or under
ÿ people with HIV, regardless of their age
ÿ healthcare workers, regardless of their age
ÿ people with evidence of scarring caused by TB, as shown on a chest 
X-ray, but who were never treated
Treatment is not recommended for people who have latent tuberculosis 
and are over 35 years of age (and do not have HIV and are not healthcare 
workers). This is because the risk of liver damage increases with age and the 
risks of treatment outweigh the benefits for some people6. Latent TB is also 
not always treated if it is suspected to be drug-resistant. If this is the case, you 
may be regularly monitored to check the infection does not become active.
In some cases, treatment for latent TB may be recommended for 
people requiring immunosuppressant medication. This medication suppresses 
the immune system (the body’s natural defense against illness and infection) 
and can allow latent TB to develop into an active form of the disease. This 
may include people taking long-term corticosteroids or people 
receiving chemotherapy3. In these cases, the TB infection should be treated 
before immunosuppressant medication begins. Treatment for latent TB 
involves either taking a combination of rifampicin and isoniazid for three 
months, or isoniazid on its own for six months1.
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By mentioning the side effects of treatment, it could be said that the 
Rifampicin can reduce the effectiveness of some types of contraception, such 
as the combined contraceptive pill. It could be said that patients should make 
use of an alternative method of contraception, such as condoms, while 
taking rifampicin2. In rare cases, these antibiotics can cause damage to the 
liver or the eyes, which can be serious. Therefore, their liver function may be 
tested before they begin treatment. If they are going to be treated with 
ethambutol, their vision should also be tested at the beginning of the course of 
treatment.
Patients have to contact their TB treatment team immediately if they
have any of the following symptoms1:
ÿ feeling sick or being sick
ÿ yellowing of your skin (jaundice) and darkening of your urine
ÿ unexplained fever - a temperature of 38C (100.4F) or above
ÿ tingling or numbness in your hands or feet
ÿ skin rash or itchy skin
ÿ changes to your vision, such as blurred vision or color blindness
For the above reasons, patients have to see medicines information for 
tuberculosis for more information about the side effects of their medication.
Sometimes people find it difficult to take their medication every day. If this 
affects them, their treatment team can work with them to find a solution. 
Usually, they will be asked to join a programme of "directly observed therapy".
This can include supervised treatment, which will involve regular contact with 
their treatment team (daily or three times a week) to support them taking their 
medication. This can take place in their home, the treatment clinic or 
somewhere else more convenient5.
As to the antibiotic-resistant tuberculosis (TB), it is mentioned that like 
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most bacteria, bacteria that cause TB can develop a resistance to antibiotics. 
This means the medicines can no longer kill the bacteria they are meant to 
fight5. Tuberculosis (TB) that develops a resistance to one type of antibiotic is 
not usually a concern because alternative antibiotics are available. In 
2011, more than 8 out of 100 cases of TB were resistant to at least one type 
of antibiotic normally used to treat the condition. Although, in a number of 
cases:
ÿ TB develops a resistance to two antibiotics - this is known as multi-
drug resistant tuberculosis (MDR-TB)
ÿ TB develops a resistance to three or more antibiotics - this is known 
as extensively drug-resistant tuberculosis (XDR-TB)
In 2011, almost 2 of every 100 TB cases were resistant to at least two 
antibiotics6. Both MDR-TB and XDR-TB will usually require treatment for at 
least 18 months using a combination of different antibiotics. As these 
conditions are difficult to treat, patients may be referred to a specialist TB 
clinic for treatment and monitoring2.
1.6 Prevention
The TB prevention consists of two main parts. The first part of TB 
prevention is to stop the transmission of TB from one person to another one. 
This is done through firstly, identifying people with active TB, and then curing 
them through the provision of drug treatment.3 With proper TB treatment
someone with active TB disease will very quickly not be infectious and so can 
no longer spread the disease to others. The second main part of TB 
prevention is to prevent people with latent TB from developing active, and 
infectious, TB disease1.
Anything which increases the number of infectious people, such as the 
presence of TB and HIV infection together, or which increases the number of 
people infected by each infectious person, such as ineffective treatment 
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because of drug resistant TB, reduces the overall effect of the main TB 
prevention efforts. As a result it is then more likely that the number of people 
globally developing active TB will increase rather than decrease. There is a 
vaccine for TB, but it makes only a small contribution to TB prevention, as it 
does little to interrupt the transmission of TB among adults2.
About the TB prevention - the BCG vaccine, it is mentioned that the TB 
vaccine called Bacillus Calmette-Guerin (BCG) was first developed in the 
1920s. It is one of the most widely used of all current vaccines, and it reaches 
more than 80% of all new born children and infants in countries where it is 
part of the national childhood immunization program. However, it is also one 
of the most variable vaccines in routine use5.
The BCG vaccine has been shown to provide children with excellent 
protection against the disseminated forms of TB, however protection against 
pulmonary TB in adults is variable. Since most transmission originates from 
adult cases of pulmonary TB, the BCG vaccine is generally used to protect 
children, rather than to interrupt transmission amongst adults. The BCG 
vaccine will often result in the person vaccinated having a positive result to a 
TB skin test2.
In case of a TB Treatment as TB prevention, it is mentioned that TB 
drug treatment for the prevention of TB, also known as chemoprophylaxis, 
can reduce the risk of a first episode of active TB occurring in people either 
exposed to infection, or with latent TB. It can also reduce the risk of a 
recurrent TB episode3. For TB prevention the World Health Organization 
(WHO) recommends the drug isoniazid should be taken daily for at least six 
months and preferably nine months.
The main "target" groups for TB treatment for prevention, are those 
most at risk of progressing from latent to active TB. These include:
ÿ Infants and children aged less than 4 years old;
ÿ People infected within the previous two years;
ÿ People infected with both TB and HIV;
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ÿ People who have certain clinical conditions or conditions which 
compromise their immune system, such as people with diabetes, and 
people with chronic renal failure.
Isoniazid is a cheap drug, but in a similar way to the use of the BCG 
vaccine, it is mainly used to protect individuals rather than to interrupt 
transmission between adults. This is because children rarely have infectious 
TB, and it is hard to administer isoniazid on a large scale to adults who do not 
have any symptoms4. Taking isoniazid daily for six months is difficult in 
respect of adherence, and as a result many individuals who could benefit from 
the treatment, stop taking the drug before the end of the six month period5.
At a Pediatric HIV/AIDS conference in Kampala, doctors were unable 
to agree as to whether children infected with HIV should be given Isoniazid as 
preventative treatment for TB. Those arguing for the drug treatment as 
prevention, claimed that in children co-infected with HIV and TB, up to 50% of 
exposed children ended up developing the disease2.
There have also been concerns about the possible impact of TB 
treatment for prevention programs on the emergence of drug resistance. 
However, a review of the scientific evidence has now shown that there is no 
need for this to be a concern. The benefit of isoniazid preventative therapy for 
people living with HIV, and who have, or may have had latent TB, has also 
recently been emphasized1.
1.7 Epidemiology
As to the epidemiology of TB, the most relevant indicators include 
actually the TB incidence, the decrease of this incidence over time, and TB 
meningitis incidence among children between 0 and 4 years of age. It is also 
important to use TB infection indicators such as infection prevalence at a 
specific age and annual infection incidence (AII). In a cohort of tuberculin skin 
test negative children, a second test must be performed after one year to 
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determine AII2. 
Although, this measurement can be difficult to perform and a bias 
exists for those who are BCG vaccinated, which produces more positive 
results and hence an inflated AII. To avoid these complications, Styblo defines 
annual risk of infection (ARI) as the prevalence of infection in two cohorts of 
the same age during consecutive years. ARI is determined by calculating the 
decline and prevalence of the last year, which should be the same as the AII. 
Styblo also estimated that 8-12 infected cases would arise from one smear-
positive TB case, even though a recent study reduced this approximation to 
2.6-5.8 because of improved TB control5.
It is mentioned that ninety-five percent of all tuberculosis cases in the 
world occur in developing countries. Tuberculosis is prevalent in Russia, 
India, Southeast Asia, sub-Saharan Africa, and parts of Latin America. 
Countries with a high prevalence of HIV infection have the greatest 
tuberculosis burden4.
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The following ten countries of origin account for the largest number of 
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In the US, over half of all active TB cases occur in immigrants. The 
reported cases of active TB in foreign-born persons has remained at 7000-
8000 per year, while the number of cases in US-born people has dropped 
from 17,000 in 1993 to 6,500 in 2005. As a result, the percentage of active TB 
cases in immigrants has increased steadily (from 29% of all cases in 1993 to 
54% in 2005).
Cases of TB in US-born vs. Foreign-born persons:
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The risk of latent disease progressing to active tuberculosis is highest 
in the first few years after immigration, which is why newly-arrived immigrants 
(within five years) are a priority for testing and treatment. However, half of all 
TB reactivations in immigrants occur after their first five years in the US, so 
testing this group should be encouraged as well. TB Cases in Foreign-born 
Persons, by Duration of US residence (2005).
1.8 Characteristics of Salicylanilides
Salicylanilide is a chemical compound which is the amide of salicylic 
acid and aniline. It is classified as both a salicylamide and an anilide. 
Derivatives of salicylanilide have a variety of pharmacological uses. 
Chlorinated derivatives including niclosamide, oxyclozanide, and rafoxanide 
are used as anthelmintics, especially as flukicides7. Brominated derivatives 
including dibromsalan, metabromsalan, and tribromsalan are used as 





1.9 Effect of Salicylanilides in Anti-tuberculosis Drugs
It is obvious that salicylanilide esters are generally more active against 
M. tuberculosis than the parent salicylanilides. Similarly, the halogenation of 
the unsubstituted salicylanilide 1a resulted in derivatives with an improved 
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antimycobacterial activity (1a versus 1b, 1c, 1d). Esters with N-acetyl-L-
phenylalanine exhibited the highest in vitro potency, followed by pyrazinoates, 
benzoates and then benzenesulfonates. Intriguingly, MIC values do not 
clearly correlate with the enzyme inhibition values corresponding to either of 
the enzymes MtMetAP1c or ICL9.
1





When MIC and the lipophilicity (calculated logP) were compared, there 
is no clear dependence; however the physico- chemical properties seem to be 
one of the factors influencing the antimycobacterial activity. The esterification 
led to the derivatives with higher lipophilicity and higher activity, but the highly 
active pyrazinoates showed lower ClogP than the parent salicylanilides. 
Similarly, the most lipophilic benzoates do not excel the MIC of esters with N-
acetyl-L-phenylalanine. Presented molecules share certain cytotoxicity, 
although the esterification of the parent salicylanilides by all organic acids 
attenuated this property9.
The hypothesis that salicylanilides and their esters act as pro- drugs for 
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the parent acids and anilines may be disproved by the fact that free acids (5-
chlorosalicylic, 4-chlorosalicylic, 5-bromosalicylic, benzoic, pyrazine-2-
carboxylic, benzenesulfonic acids and N-acetyl-L-phenylalanine) as well as 
anilines (3,4- dichloroaniline, 3-(trifluormethyl)aniline, 4-(trifluormethyl) aniline 
and 3-bromoaniline) showed only a mild antimycobacterial activity and a 
cytotoxicity significantly lower than their amides and esters. MICs of evaluated 
organic acids against M. tuberculosis were 500 mmol/L and cytotoxicities 
718.1 mmol/L; MIC of anilines are mostly >1000 mmol/L, only for 3,4-
dichloroaniline 250 mmol/L and their IC50 ranges within 413.5-1038.5 
mmol/L. 
Also the equimolar mixtures of appropriate salicylanilides with acids 
used for the esterification have not reached the antimycobacterial potencies of 
esters. It seems that both antimycobacterial and cytotoxic properties are 
predominantly associated with salicylanilide (2-hydroxy-N- phenylbenzamide) 
core in particular9.
While investigated compounds have a certain activity against 
methionine aminopeptidase, their potencies are only moderate. All 
salicylanilides 1 and their esters inhibited both human and mycobacterial 
forms of MetAPs at 10 mM in the range from 5 to 49 %. The benzoylation of 
salicylanilides led to the derivatives with decreased MetAP inhibitory activity, 
and other acyl groups did not improve the activity any further9.
Regrettably, the majority of the molecules inhibited the human enzyme 
more strongly than the MtMetAPs. This action may contribute to an 
undesirable cytotoxicity against human cells. Two derivatives 3c (the most 
favorable evaluated molecule) and 3d showed significantly higher specificity 
for the inhibition of myco- bacterial than human MetAP; four esters (3b, 3e, 
4a, 4d) expressed the equal or almost equal inhibition values for both the 
enzymes. The esterification by hydrophilic pyrazine-2-carboxylic acid provided 
the most interesting salicylanilide derivatives where the activity is retained or 
in one case certainly improved substantially towards mycobacterial enzyme 
with a desirable selectivity over the human MetAP9.
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While the inhibition of human MetAP1 may contribute to the cytotoxicity 
(similarly to antituberculosis property), the IC50 values of Hep G2 (~0.4-8.0 
μmol/L for substituted salicylanilides) do not correlate sharply with this activity, 
when described salicylanilides showed lower than 50% inhibition of hMetAP1 
at 10 μM. Additionally, hMetAP1 inhibition alone does not translate into strong 
cytotoxicity. A case in point, SB9OO64, MtMetAP1c inhibitor used as a 
positive control in this work, has an IC50 of 4.29 μM for MtMetAp1c and 0.12 
μM for hMetAP1; but 19.4 μM for HUVEC inhibition (only human cell type 
tested).
Although salicylanilide derivatives moderately affect the function of 
mycobacterial MetAP, their concentration in the assay was much higher than 
the MIC towards M. tuberculosis including drug- resistant strains. The 
explanation for their potent in vitro efficacy exclusively due to inhibition of 
MetAP is plainly inadequate; however it may contribute to the 
antimycobacterial activity9.
1.10 Mechanisms of Salicylanilide Antimicrobial Action
Salicylanilides (2-hydroxy-N-phenylbenzamides) have been used in 
medicine since the 40s. Before the inhibition of two- component regulatory 
systems (TCS) was discovered salicylanilides were considered phenols due 
to the presence of free aromatic hydroxyl group and their mechanism of 
action. The toxicity of salicylanilides to both mammalian and bacterial cells 
has largely been ascribed to their general effect on energy metabolism10.
The mechanism of action of halogenated salicylanilides, specifically 
tetrachlorosalicylanilide (3,5-dichloro-N-(3,4-dichloro- phenyl)-2-
hydroxybenzamide; was intensively studied during the 1960s. This compound 
has been found to uncouple oxidative phosphorylation in mitochondria at 0.35 
μg/cm3 and its MIC for Staphylococcus aureus was determined to be 0.15 
μg/cm3. Studies found that for a bacteriostatic effect for related compounds 
the necessary absorption is about 105 molecules per cell, and that 
salicylanilides cause leakage and membrane damage. After binding they 
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disrupt their function as the semi-permeable barrier; furthermore, several 
other effects have also been noted, e.g. terminal output domain, resulting in 
the activation or repression of genes under its control10. 
Additional levels of control and fine-tuning are achieved by specific 
phosphatase activities of the sensor kinase or aspartyl phosphatases that 
serve to limit the activation of the response regulator transcription-factor by 
the removal of phosphoryl groups in response to antithetical signal. TCS are 
often integrated into complex regulatory networks in the form of 
phosphorelays, which allow greater levels of control and facilitate the 
interpretation of multiple signals. These processes are in sharp contrast to 
eukaryotic signal transduction systems because the activation or repression of 
gene transcription is achieved through the transfer of phosphate from ATP to 
the response regulator via a high-energy phosphohistidine intermediate of the 
cognate kinase. On the other hand eukaryots employ serine/threonine and 
tyrosine kinases10.
Chemical library screening against KinA-Spo0F, a TCS which regulates 
sporulation in Bacillus subtilis, revealed that the anthelmintic closantel and the 
topical antibacterial tetrachlorosalicylanilide (inhibited autophosphorylation of 
the KinA kinase. In another study of TCS inhibitors, there was only a slight 
correlation between the inhibition of KinA-Spo0F and other enzymatic 
systems in E. coli NRII-NRI. When the molecular mechanism and the site of 
action of TCS inhibitors tetrachlorosalicylanilide and closantel were
investigated in detail, some differences were described in the molecular base 
of their action and in the efficacy. Closantel binds to the car- boxyl-terminal 
catalytic domain of the sensor kinase and causes structural changes leading 
to the aggregation10.
Tetrachlorosalicylanilide in a concentration of 0.2 μg/cm3 inhibited the 
energy-dependent cellular uptake of inorganic phosphate and amino acids, 
but not of glucose. Moreover it blocks glucose and amino acid incorporation 
into biomolecules and releases amino acids from the cell pool. In the 
concentration of 1.25 μg/cm3, tetrachlorosalicylanilide completely inhibited 
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respiration. Succine oxidase was more sensitive than was glucose oxidation 
and glucose fermentation, which were relatively indifferent to the action. 
Resistance to this class of drugs results from the inhibition of penetration 
through the cell wall. The mechanism of low activity on Gram-negative 
bacteria (MIC for Escherichia coli 30 μg/cm3) acts in the same way10.
In 1998 it was found that the sites of salicylanilide disinfectant action 
were most likely biomembranes, where they penetrate or portion into the 
phospholipid bilayer, possibly displacing phospholipide molecules. 
Salicylanilides abolish the transmembrane pH gradient and membrane 
integrity, resulting in leakage as well as the disruption of transport, respiratory 
and energy coupling processes.
The mechanism of action of salicylanilides based on the inhibition of 
two-component regulatory systems (TCS) was proposed in 1998. In all 
bacterial species there are multiple two-component systems, each controlling 
the transcription of several genes. The ubiquitous TCS are intimately involved 
in the maintenance of bacterial cell homeostasis and the expression of 
virulence factors, including resistance to antibiotics, in response to external 
and internal environmental stimuli. In many different organisms TCS regulate 
diverse responses, exceptions being virulence, further nutrient acquisition, 
energy metabolism, adaptation to physical or chemical aspects of the 
environment and complex developmental pathways. In Caulobacter 
crescentus TCS play a key role in the regulation of DNA replication and in the 
cell cycle10.
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2.The aim of the thesis
The aim of this diploma thesis was the synthesis of 5-nitrosalicylanilide 





The reactions were monitored, and the purity of products was verified 
by thin layer chromatography in which the plates were coated with 0.2 mm 
silica gel 60 F254 (Merck, Prague, Czech Republic) and visualized using UV 
irradiation (254 and 366 nm). Column chromatography was performed using 
silica gel 60 with a particle size of 0.063-0.2 mm (Fluka, Prague, Czech 
Republic). 
The melting points were determined on a Melting Point B-540 
apparatus (Bűchi Labortechnik AG, Flawil, Switzerland) in open capillaries 
and are uncorrected. IR spectra were recorded on a Nicolet 6700 FT-IR 
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) over the range of 
400-4000 cm-1 using ATR technique. The NMR spectra were measured in 
DMSO-d6 or CDCl3 solutions at ambient temperature on a Varian Mercury 
Vxbb 300 (300 MHz for 1H and 75.5 MHz for 13C, Varian Comp. Palo Alto, CA, 
USA) and Varian Mercury (500 MHz for 1H and 125 MHz for 13C, Varian 





Substituted salicylic acid (0.01mol) was dissolved in 50 ml of 
chlorobenzene, 0.01 mol of substituted aniline was added. The mixture was 
stirred 10 minutes and after that 0.435 ml (0,005 mol) of PCl3 was added drop 
by drop.
The reaction mixture was boiled under the reflux condenser in the 
microwave reactor for 20 minutes at 120 oC.






∑ 1.83 g of 2-hydroxy-5-nitrobenzoic acid
∑ 1.3932 g of 3-nitroaniline
∑ 50 ml of chlorobenzene
∑ 0.435 ml of PCl3 
∑ 1.2 ml of triethylamine
Procedure:
The mixture of the above contents was boiled in the microwave reactor 
at 120 oC and 400 watt for 20 minutes. After that, 30 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated.
This precipitate, which was named Ma 2(1), was mixed with diluted 
HCl (5ml of concentrated HCl +10 ml of distilled H2O) and let it stirred for 15 
minutes.
Then, it was filtered off and washed with distilled water. Moreover, it 
was washed with 5 ml of NaHCO3 and after that with water once more.
This solution was dried, recrystallized from ethanol and filtered off three 
times to obtain the product.
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Weight of product: 0.2042 g
Yield: 6,33%
Melting point: 235-237 oC
Chemical Formula: C13H9N3O6
Molecular Weight: 303,23
IR n(CONH-) 1626 cm-1
1H NMR (500 MHz, DMSO) δ 10.91 (1H, bs, NH), 8.76-8.73 (1H, m, H2´), 
8.69 (1H, d, J=2.4 Hz, H6), 8.29 (1H, dd, J=9.3 Hz, J=2.4 Hz, H4), 8.07 (1H, 
d, J=8.3 Hz, H6´), 8.01-7.96 (1H, m, H4´), 7.66 (1H, t, J=8.3 Hz, H5´), ), 7.16 
(1H, d, J=9.3 Hz, H3) 
13C NMR (125 MHz, DMSO) δ 164.6, 163.1, 148.1, 139.5, 139.5, 130.4, 






∑ 1.8391 g of 2-hydroxy-5-nitrobenzoic acid
∑ 2.0616 g of 3-trifluoromethyl-4-nitroaniline
∑ 50 ml of chlorobenzene
∑ 0.435 ml of PCl3 
∑ 1.2 ml of triethylamine
Procedure:
The mixture of the above contents was boiled in the microwave reactor 
at 120oC and 400 watt for 20 minutes. After that, 30 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated.
This precipitate, which was named Ma 3(1), was mixed with ethyl
acetate and heated until completely dissolved. Then HCl was added and the 
two layers, that were created, were separated.
The ethyl acetate layer (the upper part) was kept, evaporated and 
recrystallized to obtain the final product.
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Weight of product: 0.3392 g
Yield: 8,69 %
Melting point: 247-249.5 oC
Chemical Formula: C14H8F3N3O6
Molecular Weight: 371,23
IR n(CONH-) 1629 cm-1
1H NMR (300 MHz, DMSO) δ 11.17 (1H, bs, NH), 8.62 (1H, d, J=2.9 Hz, H6), 
8.44-8.38 (1H, m, H2´), 8.28 (1H, dd, J=9.1 Hz, J=2.9 Hz, H4), 8.25-8.19 (2H, 
m, H5´, H6´), 7.16 (1H, d, J=9.1 Hz, H3) 
13C NMR (75 MHz, DMSO) δ 164.7, 162.9, 143.2, 142.2, 139.4, 128.8, 127.8, 






∑ 1.8326 g of 2-hydroxy-5-nitrobenzoic acid
∑ 1.6187 g of 4-trifluoromethylaniline
∑ 50 ml of chlorobenzene
∑ 0.435 ml of PCl3 
∑ 1.2 ml of triethylamine
Procedure:
The mixture of the above contents was boiled in the microwave reactor 
at 120oC and 400 watt for 20 minutes. After that, 20 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated.
This precipitate, which was named Ma 4(1), was recrystallized and 
filtrated. The product from this filtration was mixed with ethyl acetate and 
heated until completely dissolved and then HCl was added. The two layers, 
that were created, were separated and the ethyl acetate layer (the upper part) 
was kept.
This solution was evaporated and recrystallized from ethanol to obtain 
the final product.
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Weight of product: 0.2725 g
Yield: 7,89%
Melting point: 260-261 oC
Chemical Formula: CH9F3N2O4
Molecular Weight: 326,23
IR n(CONH-) 1659 cm-1
1H NMR (300 MHz, DMSO) δ 10.79 (1H, bs, NH), 8.68 (1H, d, J=2.9 Hz,  H6), 
8.28 (1H, dd, J=9.1 Hz, J=2.9 Hz, H4), 7.98-7.89 (2H, m, AA´, BB´, H3´, H5´), 
7.77-7.68 (2H, m, AA´, BB´, H2´, H6´), 7.16 (1H, d, J=9.1 Hz, H3)
13C NMR (75 MHz, DMSO) δ 164.4, 163.0, 142.0, 139.6, 128.6, 126.3 (q, 
J=3.5 Hz), 124.9 (q, J=32.2 Hz), 124.5 (q, J=271.8 Hz), 122.7, 120.6, 120.5,
118.1






∑ 1.8336 g of 2-hydroxy-5-nitrobenzoic acid
∑ 1.6154 g of 3-trifluoromethylaniline
∑ 50 ml of chlorobenzene
∑ 0.435 ml of PCl3 
∑ 1.2 ml of triethylamine
Procedure:
The mixture of the above contents was boiled in the microwave reactor 
at 120oC and 400 watt for 20 minutes. After that, 30 ml of NaHCO3 were 
added in order to form precipitation and this precipitate (Ma 5(1)) was filtrated 
and recrystallized from ethanol.
The precipitation formed after this recrystallization, was mixed with 
ethyl acetate and heated until completely dissolved. In addition it was filtrated 
and evaporated till dryness. Then it was recrystallized from ethanol and ethyl
acetate with approximately 25 ml of diluted HCl was added, once more, 
forming two layers which were separated.
From this separation the ethyl acetate phase (upper layer) was kept 
and evaporated till dryness. The compound from that evaporation was 
recrystallized from ethanol.
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In this solution a little amount of distilled water was added and 
evaporated till dryness. Finally, distilled water was added once more and 
filtrated in order to obtain the product.
Weight of product: 0.1380 g
Yield: 4%
Melting point:  180-182 oC
Chemical Formula: C14H9F3N2O4
Molecular Weight: 326,23
IR n(CONH-) 1619 cm-1
1H NMR (300 MHz, DMSO) δ 10.78 (1H, bs, NH), 8.71 (1H, d, J=2.9 Hz, H6), 
8.28 (1H, dd, J=8.8 Hz, J=2.9 Hz, H4), 8.20 (1H, bs, H2´), 7.94 (1H, d, J=7.9 
Hz, H4´), 7.61 (1H, t, J=7.9 Hz, H5´), 7.49 (1H, d, J=7.9 Hz, H6´), 7.16 (1H, d, 
J=8.8 Hz, H3) 
13C NMR (75 MHz, DMSO) δ 164.6, 163.2, 139.5, 139.1, 130.2, 129.8 (q, 
J=32.2 Hz), 128.6, 126.0, 124.4, 124.3 (q, J=272.9 Hz), 120.1, 120.8 (q, J=3.5 
Hz), 118.1, 116.9 (q, J=3.5 Hz)





∑ 1.8413 g of 2-hydroxy-5-nitrobenzoic acid
∑ 1.7711 g of 3,4-dichloroaniline
∑ 50 ml of chlorobenzene
∑ 0.435 ml of PCl3 
∑ 1.2 ml of triethylamine
Procedure:
The mixture of the above contents was boiled in the microwave reactor 
at 120oC and 400 watt for 20 minutes. After that, 30 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated.
The product obtained from this filtration, which was named Ma 6(1), 
was mixed with ethyl acetate until completely dissolved and filtrated.
The filtrate was evaporated till dryness and then recrystallized three 
times. Moreover, ethyl acetate with approximately 25 ml of diluted HCl were 
added, forming two layers and separated.
From this separation the water phase (upper layer) was kept and 
evaporated till dryness. The compound from that evaporation was 
recrystallized from ethanol and filtrated to obtain the final product.
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Weight of product: 0.2185 g
Yield: 6,33%
Melting point: 279-281 oC
Chemical Formula: C13H8Cl2N2O4
Molecular Weight: 327,12
IR n(CONH-) 1630 cm-1
1H NMR (300 MHz, DMSO) δ10.68 (1H, bs, NH), 8.66 (1H, d, J=2.9 Hz, H6), 
8.26 (1H, dd, J=8.8 Hz, J=2.9 Hz, H4), 8.08 (1H, d, J=2.1 Hz, H2´), 7.60 (1H, 
d, J=8.8 Hz, H5´), ), 7.65 (1H, dd, J=8.8 Hz, J=2.1 Hz, H6´), 7.14 (1H, d, 
J=8.8 Hz, H3) 
13C NMR (75 MHz, DMSO) δ 164.3, 163.0, 139.5, 138.4, 131.2, 130.8, 128.6, 
126.1, 126.0, 121.9, 120.7, 120.1, 118.1 
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4. Discussion and conclusion
During my experimental work 5 products were prepared. Two of them 
were already mentioned in previous researches, 2-Hydroxy-5-nitro-N-(3-
(trifluoromethyl)phenyl)benzamide and 2-Hydroxy-5-nitro-N-(4-
(trifluoromethyl)phenyl)benzamide, but due to limited access to these 
documents , not any further information about their characteristics are 
mentioned in this diploma thesis.
According NMR spectra interpretations all prepared compounds seem 
to be in a form of phenolate triethylammonium salts. 
Unfortunately, the anti-tuberculotic activity of the prepared 
salicylanilides is not yet illustrated, since the tests are still in progress.
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